Haleon: a new addition to our long term portfolio

Haleon recently detached from its former GSK Group to form a unique healthcare group that is operating a few international brands and had the IPO in July 2022. Since then, shares have fluctuated around $8 per share, dipping to as low as $6, where investors found them very attractive. Recently, it broke its short-term $9 mark.

It is worth mentioning that the company produces well-known products like Sensodyne, Paradontax, Centrum, Theraflu, and Voltaren, among others, that are as high quality and successful as the ones mentioned above.

I am adding 100 shares to our diversified long-term portfolio with no stop loss and no target in place. It's like buying toothpaste for a lifetime, and let's hope we will not switch to pain relief products as the company slowly grows.